Search

Business & Regulation Trends & Forecasts

01/29/2025 | 2 min read

Why mRNA will be a key disrupter in the coming years; experts from CureVac and Omega Therapeutics give their views.

Manufacture Small Molecules

11/30/2022 | Catherine Jomary | 4 min read

Walking through the mRNA manufacturing process – and its many challenges.

Manufacture Vaccines

07/20/2022 | Jeneffer England | 6 min read

Optimizing mRNA in vitro transcription processes is important – and high-quality kits are a great starting point.

Manufacture Vaccines

05/08/2023 | Kyle Probst | 4 min read

Understanding the role of microbial fermentation in the production of mRNA vaccines.

Manufacture Vaccines

09/08/2020 | Amélie Boulais, Piergiuseppe Nestola

Virus-based vaccines were the first foray into immunization, but the field has had to move on and embrace new approaches.

Manufacture Technology and Equipment

04/17/2024 | Catherine Jomary, Luis Martinez Darriba | 9 min read

Lipid nanoparticles are a cornerstone of mRNA therapeutics. For manufacturing, will you choose stainless steel or single-use?

Discovery & Development Drug Discovery

02/17/2023 | Rob Coker | 3 min read

Ulrike Gnad-Vogt talks us through CureVac’s efforts to target seasonal influenza

Manufacture Bioprocessing - Upstream & Downstream

09/21/2021 | Amélie Boulais, Jay Zhang, Nitin Chopra

Manufacturers must look to ease the headaches associated with the manufacture of mRNA-based products.

Manufacture Advanced Medicine

09/30/2021 | Angus Stewart, Stephanie Vine

Could mRNA vaccine be the flu interventions of tomorrow?

Discovery & Development Vaccines

11/13/2020 | Stephanie Vine

Pfizer and BioNTech claim their two-dose COVID-19 mRNA vaccine (BNT162b2) is more than 90 percent effective.